Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV

MS patients were one of the first populations vaccinated in Iran. To date, the most used vaccine brand on Iranian MS patients is Sinopharm COVID-19 vaccine. Here is the first study on the adverse events after the first dose of Sinopharm vaccine on 583 Iranian MS patients. A Google form link was sent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali Sahraian, Mohammad, Ghadiri, Fereshteh, Azimi, Amirreza, Naser Moghadasi, Abdorreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458008/
https://www.ncbi.nlm.nih.gov/pubmed/34579974
http://dx.doi.org/10.1016/j.vaccine.2021.09.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458008/
https://www.ncbi.nlm.nih.gov/pubmed/34579974
http://dx.doi.org/10.1016/j.vaccine.2021.09.030

Ejemplares similares